307538-42-7
中文名稱
SMER28
英文名稱
SMER 28
CAS
307538-42-7
分子式
C11H10BrN3
分子量
264.12
MOL 文件
307538-42-7.mol
更新日期
2026/05/25 13:08:14
307538-42-7 結(jié)構(gòu)式
基本信息
中文別名
化合物SMER28N-烯丙基-6-溴喹唑啉-4-胺
6-溴-N-2-丙烯-1-基-4-喹唑啉胺
中文同義詞:6-溴-N-2-丙烯-1-基-4-喹唑啉胺
英文別名
CS-2308SMER 28
SMER-28
SMER 28
N-Allyl-6-bromoquinazolin-4-amine
SMER28 - CAS 307538-42-7 - Calbiochem
6-BroMo-N-2-propenyl-4-QuinazolinaMine
6-Bromo-N-prop-2-enylquinazolin-4-amine
6-BroMo-N-2-propen-1-yl-4-quinazolinaMine
4-Quinazolinamine, 6-bromo-N-2-propen-1-yl-
所屬類別
生物化工：激動劑抑制劑物理化學(xué)性質(zhì)
熔點(diǎn)171-173 °C
沸點(diǎn)391.6±32.0 °C(Predicted)
密度1.520±0.06 g/cm3(Predicted)
儲存條件2-8°C
溶解度二甲基亞砜：>20mg/mL
酸度系數(shù)(pKa)6.12±0.50(Predicted)
形態(tài)固體
顏色米色
穩(wěn)定性Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.
InChI1S/C11H10BrN3/c1-2-5-13-11-9-6-8(12)3-4-10(9)14-7-15-11/h2-4,6-7H,1,5H2,(H,13,14,15)
InChIKeyBCPOLXUSCUFDGE-UHFFFAOYSA-N
SMILESBrc1ccc2ncnc(NCC=C)c2c1
安全數(shù)據(jù)
警示詞危險(xiǎn)
危險(xiǎn)性描述H315-H318-H335
危險(xiǎn)品標(biāo)志Xi
危險(xiǎn)類別碼37/38-41
安全說明26-36/37
WGK Germany3
海關(guān)編碼2933.59.8000
存儲類別11 - Combustible Solids
SMER28價格(試劑級)
| 報(bào)價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2026/06/05 | HY-100200 | SMER28 | 307538-42-7 | 1 mg | 250元 |
| 2026/06/05 | HY-100200 | SMER28 SMER28 | 307538-42-7 | 5mg | 500元 |
| 2026/06/05 | HY-100200 | SMER28 SMER28 | 307538-42-7 | 10mM * 1mLin DMSO | 550元 |
常見問題列表
生物活性
SMER28 是一個調(diào)節(jié)自噬的、獨(dú)立于 mTOR 信號通路機(jī)制的小分子陽性調(diào)節(jié)劑，能夠阻止β淀粉樣蛋白肽的累積。體外研究
SMER28 (5-200 μM; 24 hours) shows a dose dependent decline of cell viability.
Cell Viability Assay
| Cell Line: | MMS1 cells |
| Concentration: | 5, 25, 50, 75, 100, 150, 200 μM |
| Incubation Time: | 24 hours |
| Result: | Showed a dose dependent decline of cell viability. |
體內(nèi)研究
SMER28 (15-65 mg/kg; i.h.; daily, two days before irradiation and during the three days of irradiation) significantly protects against post-irradiation weight loss and enhances survival of mice at 65 mg/kg.
| Animal Model: | 14 to 16 weeks male mice (Balb/c) |
| Dosage: | 15, 65 mg/kg |
| Administration: | Subcutaneous injection; two days before irradiation and during the three days of irradiation (total 5 days) |
| Result: | Significantly protected against post-irradiation weight loss and enhanced survival of mice at 65 mg/kg. |